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SUMMARY
We report a case of posterior non-arteritic ischaemic
optic neuropathy (NAION) causing bilateral visual loss in
a 7-month-old female infant, after a therapeutic course
with sildenafil, a phosphodiesterase type 5 inhibitors
(PDE5i). The patient was affected by a complex cyanotic
congenital heart defect and had undergone
cavopulmonary anastomosis (Glenn operation) 3 months
ago. After 2 months of recurring chylothorax, a course of
oral sildenafil was administered, with the hypothesis that
pulmonary vascular resistances were increased.
Approximately 4 weeks later the acute onset of visual
worsening and poor pupillary light reflex prompted the
diagnosis of posterior NAION. Despite a rapid cessation
of PDE5i and systemic treatment with corticosteroids, no
visual recovery was noticed at 2-year follow-up. NAION
has been associated with PDE5i therapy in adults, but to
the best of our knowledge it is almost unheard of in
children. We suggest close monitoring of visual function
in children undergoing treatment with sildenafil.
BACKGROUND
Phosphodiesterase type 5 (PDE5) inhibitors (PDE5i)
are considered standard care in adult patients with
arterial pulmonary hypertension (PH), but are also
frequently prescribed off-label in children with PH,
even though their use remains controversial.1 2
Non-arteritic ischaemic optic neuropathy
(NAION) may involve the head or the rest of the
optic nerve, causing serious visual dysfunction or
even blindness.3 NAION has been described as a
potential complication in adults on demand
therapy with PDE5i for sexual dysfunction.4
Clinically, it may manifest as unilateral or bilateral
visual loss, which could be either transient or per-
manent. To the best of our knowledge, this severe
adverse event has not been observed in adult car-
diopathic patients on PDE5i therapy, while there is
just one case described in a 6-year-old girl with
multiple congenital cardiac anomalies.5
In our patient, NAION was posterior and
resulted in complete and persistent bilateral visual
loss, strongly believed to be associated with sildena-
fil treatment.
CASE PRESENTATION
Family history was unremarkable (no ocular pro-
blems or autoimmune disease).
The patient had preterm birth for maternal pre-
eclampsia (34 weeks gestational age, birth weight
2480 g). At birth an echocardiography confirmed
the prenatal diagnosis of double inlet left ventricle,
hypoplastic right ventricle, ventricular septal defect
and moderate subpulmonary obstruction.
After 3 weeks of uneventful hospital care, the
neonate was discharged with satisfactory haemo-
dynamic parameters and about 85% oxygen satur-
ation in room air. Weight at discharge was 2630 g.
Four months after discharge from hospital the
patient was becoming tired while feeding. Clinical
examination revealed respiratory distress, lower
peripheral oxygen saturation in room air (75%)
and hepatomegaly. The infant underwent a cardiac
catheterisation procedure, which demonstrated she
was suitable for cavopulmonary anastomosis: mean
pulmonary artery pressure=14 mm Hg, wedge
pressure=9 mm Hg, transpulmonary gradient
5 mm Hg and Nakata index 520 mm2/m2. On the
following day, a Glenn operation was successfully
performed.
The postoperative period was, however, charac-
terised by recurrent pleural effusions and chy-
lothorax, treated with multiple drainages,
parenteral nutrition, fluid restriction and diuretics,
with occasional need for oxygen supplementation.
Of note, the weight of the child remained fairly
stable before and after the Glenn operation,
ranging from 4.2 to 4.5 kg in the following
2 months, suggesting she was not accumulating
excessive amount of fluids. Serial echocardiograms
performed during her paediatric intensive care unit
(PICU) stay showed a patent anastomosis, as well as
good function of the left ventricle and atrioven-
tricular valve, with 80% peripheral oxygen satur-
ation. Of note, systemic blood pressure was
persistently at 90th–95th centile for age.
After 2 months of constant recurrence of chy-
lothorax, which was refractory to rigid fluid restric-
tion regimen, diuretics and total parenteral
nutrition, we began oral sildenafil at 0.2 mg/kg
three times a day, with the hypothesis that pulmon-
ary vascular resistances and mean pressure in the
Glenn circuit were increased. Although a cardiac
catheterisation would have been useful in clarifying
this issue, we thought the procedure to be too inva-
sive, given the haemodynamic stability of the child.
Thus, we tried sildenafil as an ex juvantibus
approach, hoping to promote forward flow into the
lungs and reduce any lymphatic ‘engorgement’.
In the mean time, no episodes of hypoxaemia
were observed.
Approximately 4 weeks later, during daily clinical
examination in the PICU a lack of visual focus on
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moving objects was observed, with poor pupillary light reflex.
According to the nursing report, the baby had been fretful for a
few days.
INVESTIGATIONS
Haematocrit was 31% and haemoglobin 9.5 g/dL. Coagulation
parameters were normal. C reactive protein was normal, even
though the child was on vancomycin and amikacin for a previ-
ous infection (sepsis from Escherichia coli, with no haemo-
dynamic instability).
EEG, brain ultrasound, CT scan and MRI including eyeballs,
optic nerves, retrobulbar adipose tissue, retrobulbar muscle
cones and optic chiasma were unremarkable. A complete oph-
thalmological examination revealed bilaterally: aimless pendular
nystagmus, absent pupillary reflex, transparent crystalline lens,
light pallor optic disc, arterial venous tortuous vessels, peripapil-
lary retinal haemorrhages and macular exudation. This was the
first ocular examination since her birth. Given the sudden onset
of visual loss with optic disc pallor, in the absence of any other
ocular, neurological and orbital abnormality, the diagnosis of
posterior NAION was made.
DIFFERENTIAL DIAGNOSIS
Sudden vision loss is usually caused by a reduction of the arter-
ial blood flow to the eyes, resulting in temporary or permanent
damage. Ischaemia is usually the main cause, due to systemic
hypotension and hypertension, inflamed and swollen blood
vessel in autoimmune giant cell arteritis, peripheral vascular dis-
eases, vasculitis and increased intracranial pressure. Other causes
may be tumour compression, infection or trauma. Among the
ischaemic forms, posterior ischaemic optic neuropathy involves
the posterior part of the optic nerve and is a cause of acute and
painless visual loss, mainly in middle-aged or elderly patients.
Apart from the postsurgical type, which is usually linked to pro-
longed arterial hypotension during main surgical procedures,
with visual loss detectable as soon as the patient is awake,
ischaemic optic neuropathy can be classified in arteritic (due to
giant cell arteritis) and non-arteritic types. In its posterior form,
NAION seems to have a multifactorial pathogenesis with differ-
ent risk factors, including arterial hypertension, diabetes melli-
tus, ischaemic heart disease, cerebrovascular disease, carotid
artery and peripheral vascular disease. Aggressive high-dose sys-
temic steroid therapy in the early stage of posterior NAION can
improve visual function, but some untreated patients may show
spontaneous improvement in visual acuity and visual field.3
TREATMENT
The patient was on sildenafil (0.2 mg/kg three times a day,
started 4 weeks before), aspirin, hydrochlorothiazide/spironolac-
tone, furosemide and ranitidine.
As soon as the diagnosis of posterior NAION was made, sil-
denafil was immediately suspended, while methylprednisolone
intravenously (0.5 mg/kg, four times a day) was started, as sug-
gested in the literature.4 In addition, captopril was introduced
for a better control of blood pressure, which however persisted
at 90th–95th centile levels for age.
OUTCOME AND FOLLOW-UP
A considerable reduction of retinal haemorrhages, macular
exudation and arterial venous tortuosity was noted 1 week later.
Unfortunately, there were no visual evoked potentials after
1 Hz (0.72 J) stimulation.
Approximately 3 weeks following ocular diagnosis the patient
was discharged on diuretics, aspirin, captopril and
methylprednisolone tapering. Ophthalmological examination
revealed a complete reabsorption of retinal haemorrhages and
macular exudation, bilaterally.
At 1 year follow-up little visual recovery was noticed, while
optic disc subatrophy had worsened bilaterally.
DISCUSSION
To the best of our knowledge, this is the first reported case of
serious ocular adverse effect caused by posterior NAION asso-
ciated with the intake of a PDE5i in a young infant.
The pharmacological action of sildenafil consists of a specific
inhibition of the enzyme PDE5.4
PDE5 acts on the cyclic guanosine monophosphate pathway and
its final effect is mainly vasoconstriction due to increased intracellu-
lar calcium and potassium concentrations. PDE5 is expressed in dif-
ferent tissues. In the vascular bed its expression is almost selective
on the pulmonary vascular side, with minimal concentration in sys-
temic vessels. This enzyme is responsible for the main vascular
remodelling in arterial PH, which includes vasoconstriction,
smooth-muscle cells proliferation and vascular wall cells apoptosis.
In addition, PDE5 decreases right ventricle contractility.4 6
In the ocular system, PDE5i act on PDE5 expressed on retinal
and choroid vessels and, to a lesser degree, on PDE6 located on
retinal rods and cones.
In 1998, the Food and Drug Administration first approved sil-
denafil for the treatment of erectile dysfunction, thanks to
high-PDE5 concentrations located in the corpus cavernosum.7
Subsequently, in 2005, sildenafil was approved for the treatment
of pulmonary arterial hypertension in adults.8
Usually PDE5i are well-tolerated drugs. Most frequent side
effects observed in the postmarketing phase include headache,
facial flushing, epistaxis, nausea and dyspepsia, while changes in
lightness and colour perception have been rarely reported.9
Occasional serious adverse events associated with sildenafil
include central retinal vein occlusion, optic atrophy and cilioret-
inal artery occlusion.4 Interestingly, also NAION has been indi-
cated as potentially related to sildenafil use.4 9
Eye-related side effects are supposed to be due either to an
alteration of the ocular vascular autoregulation or due to relative
hypotension.10 To date, most of the reported cases involve
adults, using sildenafil on demand and with concomitant risk
factors for NAION, such as diabetes, dyslipidemia, coronary
and vascular diseases.4 9 When related to sildenafil use, NAION
has been described as mainly anterior, with unilateral and bilat-
eral eye involvement. In some cases visual acuity may recover
after PDE5i suspension.4 Reassuringly, a recent randomised
placebo-controlled study, performed in 277 adults in chronic sil-
denafil therapy for PH, demonstrated a good ocular safety
profile and no detrimental effect on mean intraocular pressure,
visual acuity, contrast sensitivity, colour vision and visual field.11
Despite that PDE5i are not yet formally approved in the paedi-
atric population, these drugs are frequently used as acute or
chronic therapy in severe pulmonary diseases with subsequent PH
as well as in congenital heart defects with evidence of PH.2 12 13
Our report describes an extremely serious adverse event in a 7--
month-old female infant treated with sildenafil, causing bilateral
visual loss with no evidence of recovery after drug discontinuation.
The only paediatric case of vision loss likely due to sildenafil
treatment was reported in a 6-year-old girl, who was on sildena-
fil therapy for 15 months after cardiac surgery and developed
monocular anterior NAION.5
In our case, NAION was bilateral and posterior. Visual acuity
has not shown any improvement in the 24 months since treat-
ment was discontinued.
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Our patient had no previous ophthalmological examination
so we cannot exclude if any optic disturbance was already
present, but she had no risk factors for NAION and visual func-
tion was suddenly lost after 4 weeks of sildenafil therapy.
Despite systemic blood pressure was persistently found at upper
normal levels for age, it was constantly monitored and no major
events, including hypotensive and severe hypertensive episodes,
have been registered during her PICU stay.
We also considered whether Glenn operation could have had
any role in this serious complication. Indeed, cavopulmonary
anastomosis does alter the rheology of upper limb systemic vein
drainage, especially in the first period after the operation, thus
potentially influencing blood flow regulation also at the ocular
level. Nevertheless, after an extensive review of the literature,
we could not find any reported case about ocular adverse effects
somehow related with Glenn operation.
As NAION has been already associated with PDE5i use in
adults, we speculate that a similar phenomenon could have hap-
pened also in our young patient, involving the posterior part of
the optic nerve.
We believe this quite alarming case needs to open the discus-
sion about the safety of sildenafil in paediatric patients. Further
studies will have to better elucidate the role and indication of an
ophthalmological evaluation before PDE5i therapy, as well as
the need of a strict follow-up schedule in children undergoing
prolonged PDE5i treatment.
Learning points
▸ Sildenafil, a phosphodiesterase type 5 inhibitor, is an
off-label drug in patients under 18 years of age. Despite
this, sildenafil is frequently used for pulmonary hypertension
in paediatric patients.
▸ Although very few studies have reported serious visual
adverse effects associated with sildenafil in children, there
could be a potential risk of sildenafil use in this population.
▸ Ophthalmological examination may be indicated in infants
and children before and during sildenafil treatment for
pulmonary hypertension.
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